3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Lymphoma, B-Cell
17
Lymphoma, Large B-Cell, Diffuse
16
Lymphoma, Non-Hodgkin
12
Recurrence
11
Burkitt Lymphoma
10
Multiple Myeloma
7
Lymphoma
7
Neoplasms
6
Leukemia, Myeloid, Acute
6
Lymphoma, Mantle-Cell
5
Leukemia
5
Pancreatic Neoplasms
4
Lymphoma, Follicular
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Hematologic Neoplasms
4
Carcinoma, Hepatocellular
4
Neoplasm, Residual
3
Nasopharyngeal Carcinoma
3
Leukemia, B-Cell
3
Glioma
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Stomach Neoplasms
2
Simpson-Golabi-Behmel syndrome
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Osteosarcoma
2
Melanoma
2
Lymphoma, B-Cell, Marginal Zone
2
Interventions
fludarabine
9
Cytarabine
9
venetoclax
5
fludarabine phosphate
5
Cyclophosphamide
5
Busulfan
5
thymoglobulin
4
Tacrolimus
4
Sirolimus
4
Mycophenolic Acid
4
Methotrexate
4
Azacitidine
4
aldesleukin
3
Whole-Body Irradiation
3
Interleukin-2
3
Antilymphocyte Serum
3
asciminib
2
Thiotepa
2
Peripheral Blood Stem Cell Transplantation
2
Mitoxantrone
2
Idarubicin
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Etoposide
2
Dasatinib
2
Cyclosporine
2
Bone Marrow Transplantation
2
Blood Specimen Collection
2
Behavior Therapy
2
zileuton
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, Myeloid
×
Immunotherapy, Adoptive
×
Clear all
NCT01864902
2016-01-28
CART33
Chinese PLA General Hospital
Phase 1/2
Unknown
10 enrolled